QNCX

Quince Therapeutics, Inc.

NASDAQ: QNCX · HEALTHCARE · BIOTECHNOLOGY

$29.55

+2.04% today

Updated 2026-09-11

Market cap

$31.85M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-210.84

Dividend yield

—

52W range

$15 – $910

Volume

0.0M

Market cap

$31.85M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-210.84

Dividend yield

—

52W range

$15 – $910

Volume

0.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.8

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-10.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →251 stocks currently score above 75

Price targets

Analyst target

$77.20

+161.25%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy5 Buy2 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -10.00 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-18.89M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	—
Net income	$-51.66M	$-31.39M	$-56.83M	$-83.98M	$-75.49M
EPS	—	—	—	—	$-210.84
Free cash flow	$-44.17M	$-18.45M	$-32.16M	$-41.78M	$-18.89M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
QNCX	$31.85M	24	4.3	3.0	5.0	4.8	—	Avoid
LLY	$994.92B	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$640.02B	59	4.7	8.5	2.7	6.0	-88.93%	Buy
ABBV	$454.36B	73	6.7	8.5	4.0	5.0	-69.36%	Strong Buy
MRK	$355.10B	36	4.0	4.5	2.0	5.0	-73.74%	Hold
UNH	$340.27B	62	7.3	5.5	4.7	6.0	-16.10%	Buy

Smart narrative

Quince Therapeutics, Inc. trades at $29.55. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -10.00, it sits in the distress.

Frequently asked questions

What is Quince Therapeutics, Inc.'s stock price?

Quince Therapeutics, Inc. (QNCX) trades at $29.55.

Is Quince Therapeutics, Inc. overvalued?

Quince Therapeutics, Inc. carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Quince Therapeutics, Inc. (QNCX)?

The 12-month analyst consensus target is $77.20, about 161.3% above the current $29.55. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Quince Therapeutics, Inc.'s Altman Z-Score is -10.00, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-210.80%

Beta1.31

50D MA$24.91

200D MA$177.13

Shares out0.00B

Float0.00B

Short ratio—

Avg volume0.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

QNCX vs LLY →QNCX vs JNJ →QNCX vs ABBV →Stock screener →